Endologix, Inc. (ELGX): Price and Financial Metrics

Endologix, Inc. (ELGX): $0.22

0.07 (-23.88%)

POWR Rating

Component Grades








Add ELGX to Watchlist
Sign Up

Industry: Medical - Devices & Equipment




in industry

ELGX Price/Volume Stats

Current price $0.22 52-week high $7.10
Prev. close $0.29 52-week low $0.22
Day low $0.22 Volume 7,798,100
Day high $0.28 Avg. volume 1,278,341
50-day MA $0.77 Dividend yield N/A
200-day MA $1.58 Market Cap 4.22M

ELGX Stock Price Chart Interactive Chart >

Endologix, Inc. (ELGX) Company Bio

Endologix develops and manufactures minimally invasive treatments for aortic disorders. The company was founded in 1992 and is based in Irvine, California.

ELGX Latest News Stream

Event/Time News Detail
Loading, please wait...

ELGX Latest Social Stream

Loading social stream, please wait...

View Full ELGX Social Stream

Latest ELGX News From Around the Web

Below are the latest news stories about Endologix Inc that investors may wish to consider to help them evaluate ELGX as an investment opportunity.

Endologix plunges 41% after filing for Chapter 11

After evaluating a variety of strategic options, Endologix (ELGX) has initiated a voluntary case under Chapter 11 of the U.S. Bankruptcy Code and simultaneously filed a consensual plan of reorganization supported by Deerfield Partners as its largest creditor.The financial reorganization would reduce ~$180M in debt and will provide an ~$30M in additional exit financing.Endologix also...

Seeking Alpha | July 6, 2020

Endologix's stock plunges toward record low after bankruptcy filing

Shares of Endologix Inc. plunged 41% toward a record low in premarket trading Monday, after the medical device maker filed for bankruptcy over the weekend, and announced a deal to be taken private by its largest creditor Deerfield Partners. The company said the reorganization will reduce debt by about $180 million. Endologix also expects $30.8 million in debtor-in-possession financing from Deerfield, an additional $30 million in exit financing from Deerfield and $50 million in rolled over debt. Endologix said it fully intends to meet its financial obligations during the reorganization, including paying its suppliers. The stock had rallied 20.3% over the past three months through Thursday but had tumbled 51.3% year to date, while the S&P 500 has lost 3.1%.

Yahoo | July 6, 2020

Endologix Enters into an Agreement with Deerfield Partners to Take the Company Private

Endologix Enters into an Agreement with Deerfield Partners to Take the Company Private

Yahoo | July 6, 2020

Sight Sciences Strengthens Its Leadership Team with Chief Operating Officer and General Counsel Hires

Sight Sciences, Inc., a growth-stage medical device company transforming the two fastest-growing segments in ophthalmology and optometry, glaucoma and dry eye disease, today announced two key hires: Sam Park, joining as Chief Operating Officer, and Jeremy Hayden, who joins as General Counsel and Chief Compliance Officer.

Yahoo | June 25, 2020

Edited Transcript of ELGX earnings conference call or presentation 11-May-20 8:30pm GMT

Q1 2020 Endologix Inc Earnings Call

Yahoo | June 23, 2020

Read More 'ELGX' Stories Here

ELGX Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year -96.88%
2023 N/A
2022 N/A
2021 N/A
2020 0.00%
2019 -78.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!